In vitro characterization of neurite extension using induced pluripotent stem cells derived from lissencephaly patients with TUBA1A missense mutations
- 3.3k Downloads
Lissencephaly, or smooth brain, is a severe congenital brain malformation that is thought to be associated with impaired neuronal migration during corticogenesis. However, the exact etiology of lissencephaly in humans remains unknown. Research on congenital diseases is limited by the shortage of clinically derived resources, especially for rare pediatric diseases. The research on lissencephaly is further limited because gyration in humans is more evolved than that in model animals such as mice. To overcome these limitations, we generated induced pluripotent stem cells (iPSCs) from the umbilical cord and peripheral blood of two lissencephaly patients with different clinical severities carrying alpha tubulin (TUBA1A) missense mutations (Patient A, p.N329S; Patient B, p.R264C).
Neural progenitor cells were generated from these iPSCs (iPSC-NPCs) using SMAD signaling inhibitors. These iPSC-NPCs expressed TUBA1A at much higher levels than undifferentiated iPSCs and, like fetal NPCs, readily differentiated into neurons. Using these lissencephaly iPSC-NPCs, we showed that the neurons derived from the iPSCs obtained from Patient A but not those obtained from Patient B showed abnormal neurite extension, which correlated with the pathological severity in the brains of the patients.
We established iPSCs derived from lissencephaly patients and successfully modeled one aspect of the pathogenesis of lissencephaly in vitro using iPSC-NPCs and iPSC-derived neurons. The iPSCs from patients with brain malformation diseases helped us understand the mechanism underlying rare diseases and human corticogenesis without the use of postmortem brains.
KeywordsLissencephaly Induced pluripotent stem cells TUBA1A Neural progenitor cells
Dysfunction in the complicated cellular dynamics involved in the development of the cerebral cortex causes various congenital brain malformations during different stages of the development of the central nervous system (CNS) . The two major modes of development in the human cerebral cortex are tangential and radial expansion. Tangential expansion evolves as the number of progenitor cells increases, as observed recently in the outer subventricular zone radial glia of gyrencephalic species including humans [2, 3]. A decreased number or abnormal division of progenitor cells leads to microcephaly, or small brain. Radial expansion depends on neuronal migration in a basal to apical direction along the processes of the radial glia, and dysfunction in this process impairs corticogenesis in lissencephaly.
Lissencephaly, with disturbed cerebral cortical lamination, is one of the most severe brain malformations. In lissencephaly, the surface of the brain appears smooth owing to insufficient gyration, which is why this condition is called smooth brain. Lissencephaly is mainly caused by mutations in genes, many of which are involved in microtubule function. In addition to the genes encoding microtubule-associated proteins, alpha tubulin (TUBA1A) mutations have recently been shown to cause abnormal neuronal migration . In humans, TUBA1A mutations have been identified in lissencephaly patients whose brains showed a smooth surface owing to severely impaired lamination of the cerebral cortex [4, 5, 6]. Lissencephaly in humans is an extremely rare disease, and lissencephaly patients often die within a few years, thus making it difficult to obtain viable patient-derived cells including neurons. This limitation has greatly restricted the complete elucidation of the etiology of lissencephaly in humans.
Therefore, to investigate the pathogenic mechanisms underlying lissencephaly in humans, we established induced pluripotent stem cells (iPSCs) from lissencephaly patients. Using neural progenitor cells and neurons generated from patient-derived iPSCs, we aimed to elucidate the disease pathology and to develop novel therapies.
Generation of iPSCs
Peripheral blood mononuclear cells (PBMCs) from Patient B with the p.R264C TUBA1A mutation (Fig. 1) and from a healthy adult volunteer were isolated using Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions. The isolated PBMCs were activated with immobilized anti-CD3 monoclonal antibodies (Orthoclone OKTR3 Injection, Janssen-Kyowa, Tokyo, Japan) and expanded in soluble interleukin (IL)-2-containing ALyS203 medium (NIPRO, Japan) with 10 % FBS as previously described, with minor modifications . In this study, we used the human iPSC line (201B7)  derived from human dermal fibroblasts from the facial dermis of a 36-year-old Caucasian female as the control (obtained from the RIKEN cell bank (Tsukuba, Japan)).
For iPSC generation, reprogramming episomal vectors (see below) were nucleofected using Amaxa Nucleofector I (a Neonatal Fibroblast Nucleofector Kit with the U-020 program for UCCs and a Human T cell Nucleofector Kit with the T-023 program for PBMCs; Lonza, Basel, Switzerland). Plasmids were used with combinations of pCXLE-hOct3/4-shp53, pCXLE-hUL, and pCXLE-hSK  for UCCs and PBMCs  or pCEB-hSKO and pCEB-hULG for UCCs. All the plasmids were graciously provided by Dr. Keisuke Okita and Prof. Shinya Yamanaka (Kyoto University, Kyoto, Japan). The subsequent procedures, including colony isolation and propagation, were performed as previously described . The generated iPSCs were characterized using immunocytochemistry for the pluripotency-associated transcription factors OCT3/4 and NANOG; quantitative RT-PCR for the marker genes OCT3/4, SOX2, NANOG, ZFP42, and DNMT3B; and PCR according to protocols provided by the Center for Developmental Biology (RIKEN, http://www.cdb.riken.jp) and the Center for iPS Cell Research and Application (Kyoto University, https://www.cira.kyoto-u.ac.jp) to confirm that the episomal vectors did not persist.
The teratoma formation assay for the iPSCs was performed with subcutaneous transplantations into NOD/Shi-SCID IL2Rγ null (NOG) mice [12, 13] in the Animal Facility of the CIEA (Central Institute for Experimental Animals, Kawasaki, Japan), in accordance with the guidelines of the Animal Care Committee at CIEA, and was approved by the Animal Care Committee at CIEA (No.11029A). The genomic sequences of TUBA1A were confirmed using previously reported methods .
Donor information and radiological findings
LIS grading 
Same mutation reported previously
Microlissencephaly with cerebellar hypoplasia
Brain stem dysfunction, seizure, and developmental delay. Died at 2 years old.
Kumar RA et al. 
Agyria-pachygyria (posterior > anterior gradient)
Intellectual delay and intractable seizures. Word speech at 3 years old. Has survived for 4 years now.
Keays DA et al. 
Gene and protein analyses
The sequences of the TUBA1A gene in this report are based on the sequences obtained from GenBank (Accession NM_006009). The protein structure of TUBA1A  was obtained from Protein Data Bank Japan (PDBj: 1JFF), and the illustration was generated using CueMol2 (http:/http://www.cuemol.org/en/).
Neural induction by dual SMAD inhibition and neurosphere propagation
The highly efficient dual inhibition of SMAD signaling was used for neural induction of the iPSCs . Briefly, the iPSCs cultured in growth-factor-reduced (GFR) Matrigel (BD Biosciences, San Diego, CA, USA)-coated dishes were collected and suspended in low-attachment dishes (Primesurface, Sumitomo Bakelite, Tokyo, Japan) to form embryoid bodies (EBs). For neural induction, the EBs were subsequently cultured in DMEM/F12 containing 5 % B27 supplement (Life Technologies), 5 % N2 supplement (Life Technologies), 20 ng/ml recombinant human (rh) basic fibroblast growth factor (bFGF) (Wako, Osaka, Japan), 10 μM SB431542 (SB; Sigma-Aldrich), and 1 μM dorsomorphin (DSM; Wako) for 2 weeks under 5 % O2. To obtain neural progenitor cells (NPCs) as neurospheres, the cell aggregates were mechanically dissociated and cultured in DMEM/F12 containing 2 % B27 supplement (Life Technologies), 20 ng/ml rh-basic fibroblast growth factor (bFGF; PeproTech, Rocky Hill NJ, USA), 20 ng/ml rh-epidermal growth factor (EGF; PeproTech), 10 ng/ml rh-leukemia inhibitory factor (LIF; Millipore, Billerica, MA, USA), and 5 μg/ml heparin (Sigma-Aldrich). The neurospheres were passaged before the center of the spheres darkened, typically every 12–14 days as described previously .
Differentiation of the iPSC-derived neurospheres
At approximately passage six, the neurospheres were plated onto GFR Matrigel (BD)-coated dishes in neurobasal medium (Life Technologies) containing 2 % B27 supplement (Life Technologies) and 2 mM L-glutamine (Life Technologies) (differentiation medium). For the PiggyBac vector transfection experiments, iPSC-derived neurospheres were used at stages beyond six passages when the regional identities could be caudalized and stably propagated. For differentiation in dissociated culture, the neurospheres were dissociated using TrypLE Select (Life technologies) for 5 min at 37 °C, and the dissociated iPSC-NPCs were seeded onto GFR-Matrigel (BD)-coated 96-well plates and 6-well plates in differentiation media.
RNA was extracted from the aggregates and neurospheres using an RNeasy Mini Kit (QIAGEN) and DNase set (QIAGEN), and cDNAs were synthesized using PrimeStarRT Reagent Kits (Takara Bio, Shiga, Japan). Quantitative PCR was performed using a PowerSYBR Green PCR Mix (Life Technologies) and an ABI7300 Real-time PCR system (Life Technologies) using gene-specific primer pairs (Additional file 1: Table S1). The expression (Ct values) of each gene was normalized to that of an internal control, and the normalized expression was compared using the ΔΔCt method as previously described . As a human telencephalic control, 201B7 iPSC-derived telencephalic SFEB (serum-free floating-culture of embryoid body-like) aggregates at day 25  were used. GDC90 human glial cell lines were used as a human glial cell control .
Visualization of the neurite extension of neurons derived from iPSCs of lissencephaly patients using the glia-supported neurite extension method
We used the human glial cell line GDC90 as a scaffold  to support the robust differentiation and neurite extension of the iPSC-derived neurons. To distinguish glial cell lines and iPSC-derived neural progenitor cells (iPSC-NPCs) and to illustrate the morphology of the neurites migrating from each iPSC-NPC-derived young neuron, the CAG promoter-driven  PiggyBac vector pPB-CAG-EGFP-neo  was nucleofected into the iPSC-derived neurospheres using Amaxa Nucleofector I (Lonza) as previously described . After positive selection using Geneticin at a concentration of 200 μg/ml (Life Technologies), the enhanced green fluorescent protein (EGFP)-labeled iPSC-NPCs were used for further analyses.
To measure the neurites migrating from the neurospheres, iPSC-NPCs (5 × 103 cells or 2.5 × 103 cells for time-lapse imaging) and GDC90s (5 × 103 cells or 7.5 × 103 cells for time-lapse imaging) were seeded and re-aggregated in low-attachment 96-well plates with spindle-shaped bottoms (Sumitomo Bakelite). After 24 h, the re-aggregated spheres were plated onto GFR-Matrigel-coated glass-bottom dishes in differentiation medium. In some experiments requiring the visualization of the glial cell line, tdTomato-labeled GDC90s  were used.
To quantify the behavior of the iPSC-NPCs derived from lissencephaly patients, the length of the EGFP-fluorescent neurites extending from the soma of the iPSC-NPCs existing at the edge of the fluorescent clusters was measured using ImageJ software on day 5. Time-lapse images during the differentiation and migration of the control and lissencephaly iPSC-derived neurons were acquired using an IncuCyte ZOOM HD (Essen BioSciences, Ann Arbor, MI, USA) every 4 h. The video files were exported in AVI format at six frames per second.
Immunocytochemistry and immunohistochemistry
Undifferentiated iPSCs, forebrain-committed neurons, and neurospheres were fixed in 4 % paraformaldehyde and stained using primary and secondary antibodies as described below. The samples were examined using a confocal laser-scanning microscope (LSM510, Carl Zeiss, Hallbergmoos, Germany). The following primary antibodies were used (host, dilution, manufacturer): neuronal class III β-tubulin (TUJ1; mouse, 1:500, Covance, Princeton, NJ), brain lipid-binding protein (BLBP; rabbit, 1:500, Millipore), GFAP (rabbit, 1:80, Sigma-Aldrich), SOX1 (mouse, 1:500, BD Pharmingen), NESTIN (rabbit, 1:500  and mouse, 1:500, Millipore), GFP (mouse, 1:500, Clontech, Palo Alto, CA, USA), doublecortin (DCX; rabbit, 1:500, Cell Signaling), OCT-4 (mouse, 1:200, BD), NANOG (rabbit, 1:200, ReproCELL), TRA-1-60 (mouse, 1:200, Chemicon), SSEA-3 (rat, 1:200, Chemicon), SSEA-4 (mouse, 1:200, Chemicon), and TRA-1-81 (mouse, 1:200, Chemicon). The following secondary antibodies were used: goat anti-mouse IgG Alexa Fluor 488 (1:1000, Molecular Probes), goat anti-rabbit IgG Alexa Fluor 568 (1:1000, Molecular Probes), goat anti-rabbit IgG Alexa Fluor 488 (1:1000, Molecular Probes), goat anti-mouse IgG Alexa Fluor 648 (1:1000, Molecular Probes), goat anti-mouse IgM Alexa Fluor 568 (1:1000, Molecular Probes), goat anti-rat IgM Alexa Fluor 488 (1:1000, Molecular Probes), and goat anti-rabbit IgG Alexa Fluor 648 (1:1000, Molecular Probes).
Generation of iPSCs derived from lissencephaly patients and control iPSCs
Quantitative real-time PCR showed that these lines expressed pluripotent cell markers similar to those expressed in the human embryonic stem cells KhES1 (Additional file 2: Figure S1B). These results showed that the newly generated iPSCs differentiated into three germ layers, suggesting that they were pluripotent. PCR analysis of the genomic DNA confirmed that the episomal vector was absent in these iPSCs (Additional file 2: Figure S1C). A teratoma formation assay using subcutaneous transplantation into severely immunodeficient NOG mice was conducted to test for differentiation (Additional file 2: Figure S1D). Collectively, these findings confirmed that the established human iPSC clones in the present study met the general criteria for human iPSCs.
Generation of iPSC-NPCs using dual SMAD inhibition and neurosphere culture
TUBA1A mutation-associated lissencephaly is characterized by cerebellar hypoplasia and often involves the hypoplasia of the brain stem, including the midbrain and pons. Thus, it is important to determine the regional identity of the neurospheres generated using this method. We therefore performed expression analyses for the region-specific markers.
Interestingly, these propagated neurospheres expressed forkhead box G1 (FOXG1; a forebrain marker) at a lower level and gastrulation brain homeobox 2 (GBX2; a hindbrain marker) a higher level compared with the miniature brain called “SFEB”, which was used as a human telencephalic control and was generated using previously described methods . This result indicated that these neurospheres belonged to the caudal region, which includes the hindbrain (Fig. 3e).
Soon after differentiation, these neurospheres contained glial, neuronal, and neural progenitor cells, all of which play important roles in fetal CNS development. When the neurospheres were plated, βIII tubulin-positive neuronal cells and several BLBP-positive glial fibers spread toward the outside. BLBP-positive fibers are highly polarized and consist of long processes that extend out of the neurospheres, similar to what was observed for radial glial cells during CNS development (Fig. 3f-k).
At first, we simply compared the morphology of the differentiating neurospheres on Matrigel-coated dishes during early passages (6–8 passages) when the BLBP-positive glial fibers were often observed. From these neurospheres, many neurites extended together with BLBP-positive glial fibers after 12 days (Fig. 3f-k).
Interestingly, the neurites and glial fibers derived from the iPSC-NPCs of the lissencephaly patient A (with the p.N329S TUBA1A mutation) did not extend radially and displayed a shorter morphology (Fig. 3f-g). In contrast, the neuronal cells and glial fibers derived from the iPSC-NPCs from patient B carrying the p.R264C TUBA1A mutation projected radially (Fig. 3h-i). We believe that these results might be associated with the patient’s pathology. However, quantitative analyses of neuronal morphology was technically challenging due to significant increases in cell density during the 12 days of in vitro differentiation required. Furthermore, undifferentiated NPCs persisted in the center of the neurospheres and continued to produce newborn neurons, which would further complicate quantitative analyses of neuronal morphology such as Sholl analysis.
The number of BLBP-positive glial cells in the neurospheres was low and varied between neurospheres and cell lines, which is consistent with the results of quantitative RT-PCR for BLBP (Fig. 3d). To promote the differentiation of NPCs  and to reduce variation, establishing cultures with comparable glial content is critical. However, propagation using conditions conducive for neurospheres tends to make the iPSC-NPCs neurogenic rather than gliogenic [24, 25] (Additional file 3: Figure S2), and the precise control of the glial differentiation propensity of the iPSCs remains technically difficult. Therefore, we supplemented the cultures with human glial cells in order to induce robust and rapid differentiation of the iPSC-NPCs.
Glia-supported neurite extension with fluorescently labeled iPSC-NPCs in neurospheres
Analyses of extending neurites using glia-supported neurite extension methods
The behaviors of the patient-derived and control iPSC-NPCs were evaluated using the glia-supported neurite extension method. The measurement of neurite extension after 5 days showed that neurite extension in iPSC-NPCs derived from the patient with the p.N329S TUBA1A mutation was severely inhibited (Fig. 4f–g and l, Additional files 7 and 8: Movies S4, S5). These data suggest that neuronal cells that differentiated from the iPSC-NPCs with the p.N329S TUBA1A mutation had an immature morphology compared with those derived from the control iPSC-NPCs. We believe that this phenotype corresponded to the pathology of the developing brain because neuronal cells initially polarize from NPCs and migrate toward the cortical plate using various types of neurites, including the leading process and basal process.
This observation was also supported by the results of our experiment using human fetal forebrain-derived NPCs, in which we introduced the CMV early enhancer/chicken beta actin (CAG) promoter-driven p.N329S mutant TUBA1A using the PiggyBac transposon based vector system. The overexpression of p.N329S mutant TUBA1A significantly reduced neurite extension of human NPCs (Additional file 9: Figure S3, Additional file 10: Supplementary method), suggesting that lissencephaly related to the p.N329S TUBA1A mutation was caused by a dominant-negative effect. Together with the results of our experiments described above, we concluded that we had successfully modeled one aspect of the pathology of lissencephaly in vitro using patient-derived iPSC-NPCs with the p.N329S TUBA1A mutation.
In contrast, we did not identify any phenotypic difference between the iPSC-NPCs with a p.R264C TUBA1A mutation and those derived from the controls (Fig. 4h–k, Additional file 11: Movie S6). One reason for this result may be the disease severity of the patient. The corpus callosum was missing in Patient A (with the N329S mutation), (Fig. 1a-b, Fig. 4m) whereas it is detectable in Patient B (with the p.R264C mutation), as determined from the MR images (Fig. 1c-d, Fig. 4n), suggesting that neurite extension was not as severely affected in Patient B as in Patient A. This finding is consistent with our present in vitro results obtained by measuring neurite extension (Fig. 4l). Importantly, this result was also consistent with the gradient in the pathology along the cephalic-caudal axis, as observed in the patients. The brain stem and thalamus, which have a regional identity similar to that of our iPSC-NPCs, did not appear hypoplastic in the MR images obtained from Patient B (Fig. 1d, Table 1).
Overall, the p.N329S TUBA1A mutation observed in Patient A showed reduced neurite extension that was caused by mutated tubulin in a dominant-negative manner. In contrast, the neurons generated from the iPSCs from Patient B with the p.R264C TUBA1A mutation showed no overt defects in neurite extension. This difference was consistent with the radiological pathology of the TUBA1A lissencephaly patients.
In the present study, we established iPSCs from an easily accessible cell source from patients with lissencephaly and successfully characterized the abnormalities of the iPSC-derived neurons in vitro. Recent progress in cell reprogramming methods enabled us to generate iPSCs from a variety of cell sources [9, 11, 26]. For research on human congenital brain malformations, the utility of patient-derived iPSCs overcomes the hurdles that arise owing to the lack of availability of patient-derived cells in extremely rare diseases. Furthermore, we successfully converted these cells into expandable and easy-to-handle iPSC-NPCs using neurosphere culture technology; these resources will be useful in human congenital malformation research in the future.
Lissencephaly is often caused by mutations in microtubule-associated genes . Polarized neuronal cells depend on the microtubule pathway, whereas non-polarized cells depend primarily on the driving force of actin-myosin contraction. To model lissencephaly pathology in the iPSC-NPCs, the dynamic behavior of the polarized neuronal cells must be visualized.
Spontaneously differentiating neurospheres showed extensions of small proportions of BLBP-positive radial fibers and aligned βIII tubulin-positive neurons. In our simple assay, randomly oriented neurons migrated from the neurospheres generated from the iPSCs with the p.N392S TUBA1A mutation, which might partially reflect the in vivo pathology of the patients with TUBA1A mutation-associated lissencephaly. To reduce the variation associated with the glial content of each neurosphere, we used a human glial cell line for robust and rapid neuronal differentiation. Moreover, we could observe the characteristics of the patient-derived neurons themselves without the effects of the endogenous glial cells, which might be susceptible to the effects of mutated TUBA1A or the secondary effects of abnormal neuron-mediated morphological changes that may spoil endogenous glial scaffolds . We also introduced a fluorescent protein into the iPSC-NPCs to observe the behavior of the individual cells using the PiggyBac transposon system. Interestingly, the control iPSC-NPCs in this glial cell scaffold rapidly differentiated into polarized neuronal cells with radially extending neurites. Using this system, we found that the neurite extension from the iPSC-NPCs with the p.N329S TUBA1A mutation was inhibited, whereas the iPSC-NPCs carrying the p.R264C mutation showed no apparent abnormality, indicating agenesis of the corpus callosum in Patient A with the N329S mutation. This observation suggested that patient-derived iPSC-NPCs could recapitulate the neurite extension process in the patient brain. Furthermore, neuronal cells with short neurites were also considered immature. Although we have no histological data for these patients, these neurons were considered similar to those of the patient brain because a differentiation defect manifested by immature neurons and persistent radial glia was reported previously in the TUBA1A lissencephaly patient brain . Based on our data from the iPSC-derived NPCs, we concluded that the pathology of p.N329S TUBA1A lissencephaly might start from the steps of differentiation or polarization from neural progenitor cells, leading to a migration defect in young neurons and lamination defects in the cerebral cortex. We suspect that p.N329S TUBA1A destabilizes tubulin heterodimer formation by decreasing the number of hydrogen bonds between alpha- and beta-tubulin in the neuronal cells that express abundant TUBA1A for neurite extension . This hypothesis is consistent with the dominant-negative action of p.N329S mutant TUBA1A on neurite extension, determined from the overexpression experiments (Additional file 9: Figure S3). However, considering its effects on the phenotype, the effect of overexpressing the mutant gene would be artificial. Therefore, to investigate the role of N329S, R264C, and other mutations in the disease-related phenotype, further biochemical characterizations, in patient-derived iPSCs and isogenic iPSCs introduced with these mutations by genome editing, is required in our future experiments.
As shown above, we successfully recapitulated one aspect of the pathology of lissencephaly, but the important question of whether neurons derived from a lissencephaly patient can migrate normally has not been answered. The disorganized lamination of the cerebral cortex in lissencephaly patients cannot be easily explained only by the delayed differentiation of neural progenitor cells or the delay in polarization before neuronal migration. To answer this question, further experiments involving the direct observation of migrating human iPSC-derived cortical neurons are needed. We have already generated a miniature brain from iPSCs derived from a patient with severe lissencephaly. However, unexpectedly, we found young cortical neurons located outside the germinal layer (data not shown). The exact mechanism of cortical layer formation in vitro needs to be determined before interpreting this result.
We observed translocation-like movements in this study, which led us to believe that our co-culture system might be useful in the neuronal migration of iPSC-derived telencephalic neurons.
Consistent with the MR images of the lissencephaly patient B, who had a less severe phenotype, iPSC-NPCs with the p.R264C TUBA1A mutation showed an almost normal neurite extension, although it is possible that the sensitivity of our assay system was not sufficient to detect the slight change in the phenotype. In contrast to p.N329S TUBA1A, p.R264C TUBA1A was reported to decrease the production of TUBA1A by disturbing protein folding, which might be the reason for the difference in disease severity; that is, the shortage of TUBA1A caused by the p.R264C TUBA1A mutation could be compensated for by other interchangeable α tubulin isoforms via region-specific transcriptional regulation [29, 30, 31]. Regional phenotypic differences in TUBA1A mutation-associated lissencephaly also might be partially explained by differences in the transcriptional regulation of TUBA1A throughout the brain. Further investigation into TUBA1A regulation is needed to understand the detailed mechanism of TUBA1A-associated lissencephaly.
Finally, we hypothesized that lissencephaly may provide the key to understanding other neurodevelopmental disorders. For example, the pathological analysis of postmortem brain tissue from a patient with autism revealed a partial migration defect . Moreover, the MeCP2 gene, which is associated with syndromic autism and Rett syndrome, is thought to modulate TUBA1A expression .
Thus, we believe that an experimental system using iPSC-derived neurospheres from cases of congenital brain malformation would be useful for elucidating the mechanism of the diseases and the development of the human brain.
We established iPSCs derived from two TUBA1A-associated lissencephaly patients and successfully modeled one aspect of the pathogenesis of lissencephaly in vitro using iPSC-NPCs and iPSC-derived neurons. The disease modeling using iPSCs from patients with brain malformation diseases helped us understand the mechanism underlying rare diseases and human brain development.
NPC, neural progenitor cell; iPSC, induced pluripotent stem cells; SFEB, serum-free embyoid body like aggregates; TUBA1A, alpha tubulin 1A; TUBB3, beta III tubulin; GFAP, glial fibrillary acidic protein; BLBP, brain lipid-binding protein; EGFP, enhanced green fluorescent protein; FOXG1, Forkhead box protein G1; GBX2, gastrulation brain homeobox 2
We thank Dr. Chiaki Ban, Ms. Chika Teramoto and Ms. Ai Takada for the collection of human umbilical cord tissues, and all the staff members of our laboratories and all the collaborators in the Fetal Brain Malformation (FBM) Network in Japan. Especially, we fully appreciate Hayato Fukusumi for the technical assistance in our revised manuscript. We also give our thanks for the kind gift of episomal vectors that were used in iPSC generation from Dr. Keisuke Okita and Prof. Shinya Yamanaka. This study is supported by the Research on Intractable Diseases and the Research on Applying Health Technology, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan to M.Y., and the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells funded by the Japan Science and Technology Agency (JST)/Japan Agency for Medical Research and Development (A-MED) to H.O..
This research is supported by Health and Labor Sciences Research Grants for research of intractable disease to M.Y. (Award Number: 2009-ID-028, 2010-ID-131, 2011-ID-013) and Program for Intractable Disease Research Utilizing Disease-specific iPS Cells funded by the Japan Science and Technology Agency (JST)/Japan Agency for Medical Research and Development (A-MED) to H.O.(Award Number: 0609003h).
This research was designed by YB, YK, MY, WA, and HO and was performed in the laboratory of YK and YM. The experiments were performed by YB, TS, DK and MS. The teratoma formation assay was performed by YH and HS in CIEA as described in the material and methods section. The interpretation of clinical imaging data and clinical information and the sampling of patient-derived materials were performed by MK, RKP, YT, JT, and HU. The data were analyzed by YB, TS, YK, and HO. Detailed protocols for the neural induction of pluripotent stem cells were developed and provided by DG and FDM. The conception of this research was made by YM, YK, and HO. This manuscript was written by YB, YK, MY, and HO. All the authors approved the final version of the manuscript.
Dr. H. Okano is a paid scientific consultant to SanBio Co Ltd and Eisai Co., Ltd. Dr. Y. Kanemura received research funding from Kaneka Corp. The authors declare no conflicts of interest associated with this manuscript.
Ethics approval and consent to participate and consent for publication
This study was conducted in accordance with the principles of the Helsinki Declaration, and the approval for the use of human tissues and cells and for genetic examination was obtained from the ethics committees of Osaka National Hospital and Keio University School of Medicine (No. 94, 110, 123, 146, and 150) with appropriate informed consent including participation and publication.
Fluorescent neurosphere (201B7) differentiation without glial cells. (AVI 25686 kb)
Fluorescent neurosphere (201B7) differentiation with glial cells. (AVI 30161 kb)
Translocation-like movement in differentiating fluorescent neurospheres (201B7) at high magnification. (AVI 2472 kb)
Neurite extension (201B7) with the glia-supported neurites extension method. (AVI 1390 kb)
Neurite extension (iPS-A) with the glia-supported neurites extension method. (AVI 891 kb)
Neurite extension (iPS-B) with the glia-supported neurites extension method. (AVI 1492 kb)
- 5.Kumar RA, Pilz DT, Babatz TD, Cushion TD, Harvey K, Topf M, Yates L, Robb S, Uyanik G, Mancini GM, et al. TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Hum Mol Genet. 2010;19:2817–27.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Poirier K, Keays DA, Francis F, Saillour Y, Bahi N, Manouvrier S, Fallet-Bianco C, Pasquier L, Toutain A, Tuy FP, et al. Large spectrum of lissencephaly and pachygyria phenotypes resulting from de novo missense mutations in tubulin alpha 1A (TUBA1A). Hum Mutat. 2007;28:1055–64.CrossRefPubMedGoogle Scholar
- 12.Shofuda T, Kanematsu D, Fukusumi H, Yamamoto A, Bamba Y, Yoshitatsu S, Suemizu H, Nakamura M, Sugimoto Y, Furue M, Kohara A, Akamatsu W, Okada Y, Okano H, Yamasaki M, Kanemura Y. Human decidua-derived mesenchymal cells is a promising source for generation and cell banking of human induced pluripotent stem cells. Cell Med. 2013;4:125–47.CrossRefPubMedGoogle Scholar
- 17.Kanemura Y, Mori H, Kobayashi S, Islam O, Kodama E, Yamamoto A, Nakanishi Y, Arita N, Yamasaki M, Okano H, et al. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. J Neurosci Res. 2002;69:869–79.CrossRefPubMedGoogle Scholar
- 20.Bamba Y, Shofuda T, Kanematsu D, Nonaka M, Yamasaki M, Okano H, Kanemura Y. Differentiation, polarization, and migration of human induced pluripotent stem cell-derived neural progenitor cells co-cultured with a human glial cell line with radial glial-like characteristics. Biochem Biophys Res Commun. 2014;447:683–8.CrossRefPubMedGoogle Scholar
- 24.Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain. 2012;5:35.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Falk A, Koch P, Kesavan J, Takashima Y, Ladewig J, Alexander M, Wiskow O, Tailor J, Trotter M, Pollard S, et al. Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. PLoS One. 2012;7:e29597.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Schatz PJ, Solomon F, Botstein D: Genetically essential and nonessential alpha-tubulin genes specify functionally interchangeable proteins. Mol Cell Biol. 1986;6:3722-733.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.